Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)

China · Delayed Price · Currency is CNY

34.41

-1.39 (-3.88%)

At close: Jun 24, 2026

-4.07% (1Y)

Market Cap	14.37B
Revenue (ttm)	3.78B +3.2%
Net Income	488.24M +6.7%
EPS	1.20 -2.5%
Shares Out	417.75M
PE Ratio	28.71
Forward PE	28.84
Dividend	0.52 (1.45%)
Ex-Dividend Date	Jun 1, 2026

Volume	3,747,162
Open	35.82
Previous Close	35.80
Day's Range	34.08 - 35.97
52-Week Range	29.70 - 49.01
Beta	n/a
Analysts	Strong Buy
Price Target	44.25 (+28.6%)
Earnings Date	Aug 28, 2026

About SHA:603014

Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis. The company was founded in 2004 and is based in Weihai, China. [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2004

Employees 3,734

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603014

Full Company Profile

Financial Performance

In 2025, SHA:603014's revenue was 3.77 billion, an increase of 4.57% compared to the previous year's 3.60 billion. Earnings were 482.30 million, an increase of 7.33%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 603014 stock is "Strong Buy." The 12-month stock price target is ¥44.25, which is an increase of 28.60% from the latest price.

Price Target

¥44.25

(28.60% upside)

Analyst Consensus: Strong Buy

Stock Forecasts